InnovationFixer Profile Banner
Kevin McFarthing Profile
Kevin McFarthing

@InnovationFixer

Followers
9K
Following
573
Media
189
Statuses
10K

Parkinson's research advocate, curator of the Parkinson's Hope List, used to know a lot about innovation management and R&D

Oxford, UK
Joined June 2010
Don't wanna be here? Send us removal request.
@InnovationFixer
Kevin McFarthing
11 months
The latest version of the Parkinson’s Hope List is now available at https://t.co/MXVxXMBq9W . It has 237 projects in Research stage, 98 in Discovery and 139 in Pre-clinical; and 166 in Clinical stage broken down by phase. #Parkinsons 1/2
Tweet media one
1
0
5
@InnovationFixer
Kevin McFarthing
8 days
Coincidentally in today’s Guardian -
Tweet card summary image
theguardian.com
Bluesky posts referencing scholarly articles ‘find substantially higher levels of interaction’ than on Elon Musk’s platform
@ScienceofPD
The Science of Parkinson's
8 days
It does feel like most of the academic research community has now departed Twitter (I certainly get a lot more engagement on Bluesky) Something has definitely gone wrong on this platform. Sad, but I guess all good things come to an end @elonmusk @twitter
0
1
3
@AMahajanMD
Abhimanyu Mahajan
13 days
“As such, moderation in the communication of prognosis and of the potential of new medicines is essential, so that PwP can maintain hope rather than being misled by hype.” in ⁦@journal_PD
Tweet card summary image
journals.sagepub.com
Parkinson's disease (PD) is a heterogeneous condition that presents variable clinical, neuropathological, and biomarker features. Disease progression can a...
0
2
4
@parkinsonstory
Parkinson's News Today
15 days
The Parkinson's Foundation has launched PD Trial Navigator to help increase enrollment in clinical studies testing gene-targeted therapies. https://t.co/0bvi86aYQn
Tweet media one
0
2
3
@Nature
nature
1 month
Replenishing the brain’s natural stores of lithium can protect against and even reverse Alzheimer’s disease https://t.co/Z4sUteT7jD
Tweet card summary image
nature.com
Nature - Studies in rodents and humans suggest that low levels of the metal contribute to cognitive decline.
73
782
3K
@MichaelOkun
Michael Okun
1 month
Could gene therapy silence Parkinson’s progression? A study in primates just showed it may be possible. Steece-Collier and colleagues knocked it out of the park in their new paper in Molecular Therapy. The group studied aged macaques and demonstrated that targeting CaV1.3
Tweet media one
3
10
63
@InnovationFixer
Kevin McFarthing
1 month
Shades of grey: The continuum of therapies for Parkinson's disease along the spectrum of credibility - Araceli Alonso-Canovas, Olaf M Dekkers, Bas Bloem, 2025p
Tweet card summary image
journals.sagepub.com
Complementary and alternative therapies (CAT) is an umbrella term applied to a diverse set of approaches, with high interest among persons with Parkinson's...
0
0
1
@InnovationFixer
Kevin McFarthing
1 month
Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease - Beatrice Heim, Werner Poewe, 2025
Tweet card summary image
journals.sagepub.com
Parkinson's disease (PD) is a progressive neurodegenerative disorder clinically defined by the presence of cardinal motor features like bradykinesia, rigid...
0
0
0
@MichaelOkun
Michael Okun
1 month
What are the FDA approved drugs for non-motor and neuropsychiatric symptoms in Parkinson's? We need to do better and this needs to be part of the plan. https://t.co/HgZNvTKZHu Thanks Jen Goldman for updating us on this 'lack of progress.' Let's do better as people are counting on
Tweet media one
3
6
27
@MichaelOkun
Michael Okun
2 months
Can specialized physical therapy help you to live longer with Parkinson’s? What if physical therapy did more than improve balance and reduce falls? A new Dutch study by Ypinga, Bloem and colleagues just dropped and the results are fascinating. Specialized physical therapy, like
Tweet media one
4
10
47
@MichaelOkun
Michael Okun
2 months
Dopamine acts like a laser pointer and not a sprinkler. Dopamine isn’t just about pleasure or motion, it’s about precision coding at the cellular level. Maybe we should stop stereotyping dopamine as a simple splashy brain signal. An interesting new study in Science by Yee, Ford
Tweet media one
4
11
28
@ScienceofPD
The Science of Parkinson's
2 months
Wow! Big data dump: @_neuroproteome presents 250M protein measurements from >35K biofluid samples (plasma, serum & cerebrospinal fluid) contributed by 23 partners, spanning #Alzheimers, #Parkinsons, frontotemporal dementia & #ALS; Biomarker discovery https://t.co/UT2Yg30L67
Tweet media one
Tweet media two
Tweet media three
2
3
7
@MichaelOkun
Michael Okun
2 months
It’s not just tremors in Parkinson's, we need to broaden our rehabilitation lens beyond balance and gait. We need rehabilitation strategies for sleep and autonomic symptoms like constipation, urinary and sexual dysfunction. We’ve long focused on movement, but what about the
Tweet media one
2
29
77
@InnovationFixer
Kevin McFarthing
2 months
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - BioSpace
Tweet card summary image
biospace.com
1
0
3
@moversand6
Movers & Shakers: a podcast about Parkinson's
2 months
✨ We've received a very special message from Sir Stephen Fry supporting the Parky Charter petition! ✨ ⏱️Please take this national treasure at his word and go straight to https://t.co/7P6RdRuOLc and add your signature!
1
28
50
@MichaelOkun
Michael Okun
2 months
Results are in for the first trial of Ambroxol and Parkinson’s dementia. For years, the Parkinson’s community has waited for a trial to test whether ambroxol, a common cough medicine w/ brain penetrating effects could impact Parkinson’s disease dementia also called PDD. Just
Tweet media one
7
39
118
@ScienceofPD
The Science of Parkinson's
2 months
New data "suggest that pesticide exposure & lifestyle factors may affect motor severity in patients with LRRK2-#Parkinsons & idiopathic PD, demonstrating the impact on patients even after disease onset" https://t.co/F4oxbO6aL2
Tweet media one
Tweet media two
Tweet media three
1
1
7